Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)

The introduction of tyrosine kinase inhibitors (TKIs) has improved the overall survival of chronic myeloid leukemia patients in chronic phase (CP-CML) and reduced the rate of disease-related mortality. Conflicting results have been however reported between data emerged from sponsored clinical trials...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2021-02, Vol.100 (2), p.481-485
Main Authors: Breccia, Massimo, Celant, Simone, Olimpieri, Pier Paolo, Olimpieri, Odoardo M., Pane, Fabrizio, Iurlo, Alessandra, Cirilli, Alessia, Colatrella, Antonietta, Gozzo, Lucia, Pugliese, Sara, Summa, Valentina, Foggi, Paolo, Corradini, Paolo, Russo, Pierluigi
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age Factors
Aged
Child
Child, Preschool
Databases, Factual
Female
Follow-Up Studies
Hematology
Humans
Infant
Infant, Newborn
Italy - epidemiology
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality
Male
Medicine
Medicine & Public Health
Middle Aged
Mortality
Oncology
Original Article
Protein Kinase Inhibitors - administration & dosage
Registries
Retrospective Studies
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The introduction of tyrosine kinase inhibitors (TKIs) has improved the overall survival of chronic myeloid leukemia patients in chronic phase (CP-CML) and reduced the rate of disease-related mortality. Conflicting results have been however reported between data emerged from sponsored clinical trials and from population-based registries. Moreover, no data are so far available for patients treated with frontline second-generation TKIs, excluding those from sponsored studies. We analyzed the mortality rate of 2315 CP-CML patients treated with frontline second-generation TKIs through the Italian Medicines Agency (AIFA) registries and compared it with the ISTAT mortality rate of the general population. The estimated differences show that the increased rate of mortality in CP-CML patients is less than 1% for the class 0–29 years, stable around 2% for the intervals 30–44 years and 45–59 years, and 1.4% for the interval 60–74 years; interestingly this rate is reduced for patients aged 75 years and more as compared to the general population (− 0.65%). The difference between potential and estimated deaths is higher among women in the age classes between 30 and 74 years.
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-021-04406-1